UL40 human cytomegalovirus variability evolution patterns over time in renal transplant recipients

Transplantation

Volumn 86, Issue 6, 2008, Pages 826-835

  Garrigue, Isabelle ^a,b,d   Corte, Muriel Faure Della ^a   Magnin, Noël ^a   Recordon Pinson, Patricia ^b   Couzi, Lionel ^b   Lebrette, Marie Elise ^b   Schrive, Marie Hélène ^a   Roncin, Loïc ^a,b   Taupin, Jean Luc ^c   Déchanet Merville, Julie ^c   Fleury, Hervé ^a,b   Lafon, Marie Edith ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c CNRS Bordeaux Segalen University   (France)

^d University Victor Segalen   (France)

Author keywords

Cloning; HCMV UL40; Quasispecies; Recombination; Renal transplantation

Indexed keywords

ARTICLE; CASE REPORT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GENE SEQUENCE; HUMAN; HUMAN CYTOMEGALOVIRUS; KIDNEY GRAFT; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UL40 GENE; VIRUS GENE; VIRUS STRAIN; CLASSIFICATION; CYTOMEGALOVIRUS; FOLLOW UP; GENETIC VARIABILITY; GENETICS; KIDNEY TRANSPLANTATION; MOLECULAR EVOLUTION; PATHOGENICITY; REOPERATION;

ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; UL40 GLYCOPROTEIN, CYTOMEGALOVIRUS; VIRUS PROTEIN;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EVOLUTION, MOLECULAR; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; PHYLOGENY; REOPERATION; VARIATION (GENETICS); VIRAL PROTEINS;

EID: 56049109070     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181859edd     Document Type: Article

References (46)

1. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4 + and CD8 + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673.
2. Dechanet J, Merville P, Lim A, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437.
3. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: Manipulative strategies beyond evasion. Trends Microbiol 2002; 10: 332.
4. Reeves MB, Davies AA, McSharry BP, et al. Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science 2007; 316: 1345.
5. Vossen MT, Westerhout EM, Soderberg-Naucler C, et al. Viral immune evasion: A masterpiece of evolution. Immunogenetics 2002; 54: 527.
6. Wilkinson GW, Tomasec P, Stanton RJ, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 2008; 41: 206.
7. Tomasec P, Braud VM, Rickards C, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287: 1031.
8. UlbrechtM,Martinozzi S,GrzeschikM,et al. Cutting edge: The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000; 164: 5019.
9. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795.
10. Wang EC, McSharry B, Retiere C, et al. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci USA 2002; 99: 7570.
11. Braud VM, Tomasec P, Wilkinson GW. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr Top Microbiol Immunol 2002; 269: 117.
12. Cerboni C, Mousavi-Jazi M, Wakiguchi H, et al. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 2001; 31: 2926.
13. Dolan A, Cunningham C, Hector RD, et al. Genetic content of wildtype human cytomegalovirus. J Gen Virol 2004; 85(Pt 5): 1301.
14. Murphy E, Yu D, GrimwoodJ, et al. Coding potential oflaboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA 2003; 100: 14976.
15. Rasmussen L, Geissler A, Winters M. Inter- and intragenic variations complicate the molecular epidemiology of human cytomegalovirus. J Infect Dis 2003; 187: 809.
16. Garrigue I, Faure-Della Corte M, Magnin N, et al. Variability of UL18, UL40, UL111a and US3 immunomodulatory genes among human cy-tomegalovirus clinical isolates from renal transplant recipients. J Clin Virol 2007; 40: 120.
17. Merel P, Pellegrin I, Garrigue I, et al. Comparison of capillary electro-phoresis sequencing with the new CEQ 2000 DNA analysis system to conventional gel based systems for HIV drug resistance analysis. J Virol Methods 2001; 98: 9.
18. Wolinsky SM, Korber BT, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272: 537.
19. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73: 152.
20. Norberg P, Kasubi MJ, Haarr L, et al. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 2007; 81: 13158.
21. Legrand-Abravanel F, Claudinon J, Nicot F, et al. New natural interge-notypic (2/5) recombinant of hepatitis C virus. J Virol 2007; 81: 4357.
22. Arav-Boger R, Foster CB, Zong JC, et al. Human cytomegalovirus-encoded alpha-chemokines exhibit high sequence variability in con-genitally infected newborns. J Infect Dis 2006; 193: 788.
23. AkterP,Cunningham C,McSharry BP,et al. Two novel spliced genes in human cytomegalovirus. J Gen Virol 2003; 84(Pt 5): 1117.
24. Nattermann J, Nischalke HD, Hofmeister V, et al. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 2005; 10: 95.
25. Nattermann J, Nischalke HD, Hofmeister V, et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005; 166: 443.
26. Geraghty DE, Stockschleader M, Ishitani A, et al. Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism. Hum Immunol 1992; 33: 174.
27. MatteC, Lacaille J,Zijenah L,et al. HLA-G and HLA-E polymorphisms in an indigenous African population. The ZVITAMBO study group. Hum Immunol 2000; 61: 1150.
28. Strong RK, Holmes MA, Li P, et al. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003; 278: 5082.
29. Tamouza R, Rocha V, Busson M, et al. Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation 2005; 80: 140.
30. Borrego F, Ulbrecht M, Weiss EH, et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187: 813.
31. Millo E, Pietra G, Armirotti A, et al. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context ofHLA-E. J Immunol Methods 2007; 322:128.
32. Baldanti F, Revello MG, Percivalle E, et al. Genomes of the endothelial cell-tropic variant and the parental Toledo strain of human cytomegalovirus are highly divergent. J Med Virol 2003; 69: 76.
33. Stanton R, Westmoreland D, Fox JD, et al. Stability of human cytomegalovirus genotypes in persistently infected renal transplant recipients. J Med Virol 2005; 75: 42.
34. Aquino VH, Figueiredo LT. High prevalence of renal transplant recipients infected with more than one cytomegalovirus glycoprotein B genotype. J Med Virol 2000; 61: 138.
35. Humar A, Kumar D, Gilbert C, et al. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis 2003; 188: 581.
36. Ducancelle A, Belloc S, Alain S, et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004; 29: 241.
37. Grundy JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132.
38. Arav-Boger R, Zong JC, Foster CB. Loss of linkage disequilibrium and accelerated protein divergence in duplicated cytomegalovirus chemo-kine genes. Virus Genes 2005; 31: 65.
39. Chou SW. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 1989; 160: 11.
40. Haberland M, Meyer-Konig U, Hufert FT. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J Gen Virol 1999; 80(Pt 6): 1495.
41. Benson JD, Huang ES. Human cytomegalovirus induces expression of cellular topoisomerase II. J Virol 1990; 64: 9.
42. Puchhammer-Stockl E, Gorzer I, Zoufaly A, et al. Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients. Transplantation 2006; 81: 187.
43. Zong JC, Arav-Boger R, Alcendor DJ, et al. Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes. J Clin Virol 2007; 40: 1.
44. Lafarge X, Merville P, Cazin MC, et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 2001; 184: 533.
45. Garrigue I, Boucher S, Couzi L, et al. Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients. J Clin Virol 2006; 36: 72.
46. Garrigue I, Doussau A, Asselineau J, et al. Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol 2008; 46:493.